OTR3 is a French biotechnology company specialized in therapeutic agents based on proprietary RGTA® (ReGeneraTing Agents) technology which heal lesions by restoring the extracellular matrix and cellular micro-environment.
We have demonstrated in animal models significant beneficial effects of RGTA® molecules in stroke treatment.
The potential of using RGTA® as a neuroprotectant in injured tissue represents thus a highly attractive opportunity to enhance the recovery and reduce sequalae of stroke survivors.
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.